Head-to-Head Comparison
OpenEvidence vs Epocrates: Which Is Better for Physicians?
OpenEvidence ranks #2 in our 2026 clinical decision support rankings with a 4.3-star rating from 16 physician reviews, while Epocrates ranks #6 with a 3.8-star rating from 14 reviews. OpenEvidence leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.
Feature Comparison
| Feature | OpenEvidence | Epocrates |
|---|---|---|
| Rating | Very Good | Good |
| Category | AI Medical Research Assistant | Drug Reference & Clinical Decision Support |
| Pricing | Free (Ad-Supported) | Free (Basic) / $174.99/year (Plus) |
| Founded | 2022 | 1998 |
| Headquarters | Miami, FL | San Mateo, CA |
| Evidence Citations | Yes | No |
| AI Differential Diagnosis | No | No |
| Drug Database | No | Yes |
| Drug Interaction Checker | No | Yes |
| Medical Calculators | Yes | Yes |
| Natural Language Search | Yes | No |
| Document & Image Upload | No | No |
| EHR Integration | Yes | No |
| Mobile App | Yes | Yes |
| Built-in Dialer | Yes | No |
| AI Clinical Scribe | No | No |
| CME Credits | No | No |
| Multi-Language | Yes | No |
Strengths & Limitations
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
Epocrates
Strengths
- +Free tier with genuinely useful drug interaction checker and monographs
- +Fast, well-designed mobile app optimized for point-of-care use
- +Over 1 million active healthcare professional users
- +Pill identification tool is accurate and practical
- +Affordable Plus tier at $174.99/year compared to competitors
- +Long track record since 1998 with consistent reliability
Limitations
- –No AI-powered differential diagnosis or clinical reasoning
- –Disease content lacks depth compared to UpToDate or DynaMed
- –No natural-language query support or evidence synthesis
- –Limited EHR integration for individual users
- –Plus tier content updates can lag behind newer platforms
Key Statistics
OpenEvidence
Epocrates
Citable Summaries
OpenEvidence
OpenEvidence received a Very Good rating (4.3 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking second overall. Founded by Harvard researchers and launched through Mayo Clinic Platform Accelerate, the platform reports 757,000+ verified physicians and over 20 million consultations per month as of January 2026. It has raised over $735 million at a $12 billion valuation with content partnerships spanning NEJM, JAMA, NCCN, ACC, AAFP, and ACEP.
Source: Clinical AI Report, December 2025
Epocrates
Epocrates received a Good rating (3.7 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking sixth overall. With over 1 million healthcare professional users and a strong free drug reference tier, it remains the go-to pharmacology tool at the point of care — but its lack of AI clinical reasoning features limits its ceiling in a market increasingly defined by intelligent decision support.
Source: Clinical AI Report, December 2025
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 4.3 stars) outperforms Epocrates (ranked #6, 3.8 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, Epocrates is a stronger choice for physicians and residents seeking a fast, reliable, mobile-first drug reference tool with a strong free tier — especially for interaction checks and dosing at the point of care. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.